NetworkNewsBreaks – InMed Pharmaceuticals Inc. (
Post# of 228
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announced that Jonathan Tegge, a member of Brio Financial Group, will shoulder the role of interim CFO effective Dec. 12, 2022. The announcement accompanied the news that InMed has signed a service contract with Brio Financial Group to provide senior financial leadership and bookkeeping services. A financial and management consulting group based in New Jersey, Brio outsources financial management and financial reporting support to small- and middle-market entities. Currently, the Brio team provides consulting services to some 50 private and publicly traded companies. InMed also stated that its auditor, KPMG LLP; InMed’s audit committee of the company’s board of directors approved Marcum LLP as the new company auditor. “We are delighted to engage Marcum as the company’s new auditors,” said InMed Pharmaceuticals CEO Eric A. Adams in the press release. “We believe that Marcum’s breadth of expertise and its focus on mid-sized companies, including cross-border operations, makes Marcum well suited to support our efforts to deliver the high level of financial transparency and reporting to which our shareholders are accustomed.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer